Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring
Centre Oscar Lambret
88 participants
Feb 28, 2024
INTERVENTIONAL
Conditions
Summary
This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (\<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan, established for each patient according to national guidelines, when the surveillance is conducted in person by a hospital-based physician (control arm) or remotely by a trained nurse (experimental arm).
Eligibility
Inclusion Criteria11
- Positive diagnosis (anatomopathology) of tumor within 12 months
- Patient 18 years of age or older
- Patient with one of the following conditions:
- Desmoid fibromatosis of the abdominal wall operated on or under active surveillance
- Stage I testicular seminoma (whether or not treated with carboplatin AUC7)
- Stage I non-seminomatous germ cell tumor (with or without adjuvant BEP chemotherapy)
- Operated GIST with low risk of relapse
- Rare gynecological tumors (sex cord and stromal tumors; germ cell tumors of the ovary, clear cell adenocarcinoma, mucinous adenocarcinoma of the ovary, borderline tumors, small cell carcinoma, ovarian and uterine carcinosarcoma, low grade serous tumors), operated
- Low-grade glioma, operated
- Low-grade neuroendocrine tumor, treated by surgery alone
- Patient who has given consent to participate in the study
Exclusion Criteria3
- Contraindication to imaging tests required for the surveillance plan
- No telephone
- Patient under guardianship or curatorship
Interventions
Post-cancer surveillance (including biological, clinical and imaging exams depending on the condition)
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05500391